Market Views – Page 12 – media

Magenta bags $52M Series C for bone marrow transplant pipeline

High-flying Cambridge startup Magenta has snagged $52 million in a new financing round to push forward the company’s pipeline of therapies for bone marrow transplant.
- Source: Endpts
- 475
- April 13, 2018
financing Market Views
Security Fears Outweigh Benefits in Mobile Device Management Report

A global survey of healthcare executives finds significant satisfaction in mobile device programs, but a lack of faith in mHealth security.
- Source: mHealthIntelligence
- 487
- April 13, 2018
digital health Market Views mHealth
Blockchain System Aims to Identify Health Problems Using AI

A new Blockchain platform has seemingly proven that it is possible to for AI to perform more accurate health diagnosis than human doctors, paving the way for a change in the way medical tests are performed.
- Source: Cointelegraph
- 662
- April 12, 2018
AI digital health Market Views
Strong Growth Potential in Global Clinical Trial Data Management and eClinical Solutions Market to Cross $4 Billion by 2020

Unified cloud-based eClinical platforms, with built-in scalability and modularity, will drive growth opportunities across the globe
- Source: PR Newswire
- 684
- April 12, 2018
Clinical Trial Market Views mHealth
Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics

Illumina, Inc. (Nasdaq: ILMN) and Loxo Oncology (Nasdaq: LOXO) today announced a global strategic partnership to develop and commercialize a multi-gene panel for broad tumor profiling, resulting in a distributable, next-generation sequencing (NGS) based companion diagnostic (CDx) with a pan-cancer indication.
- Source: Illumina
- 501
- April 12, 2018
larotrectinib Market Views
Alexion to buy Wilson for $855m

Alexion Pharmaceuticals has offered to buy Wilson Therapeutics in a deal worth around $855 million. Wilson is a Swedish biopharma developing novel therapies for patients with rare copper-mediated disorders.
- Source: pharmatimes
- 476
- April 12, 2018
Alexion Market Views rare copper-mediated disorders
Ionis and AstraZeneca Advance New Drug for NASH

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that it has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca (NYSE: AZN) following advancement of the drug into development. IONIS-AZ6-2.5-LRx is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis (NASH)
- Source: Prnewswire
- 624
- April 11, 2018
Market Views NASH
The top 5 mental/behavioural health startups that have raised funding

Healthcare is such a massive space, one that takes up a sixth of the entire U.S. economy, that just one small piece of that pie can be extremely lucrative. Take diabetes, for example, where there has been a slew of different companies tackling that problem, and raising money in the process, including Glooko, Omada Health, Siren and Virta Health.
- Source: VatorNews
- 1,379
- April 11, 2018
Market Views Mental health mHealth
Lilly, Sigilon Partner on Encapsulated Cell Therapies for Diabetes

Eli Lilly and Company and Sigilon Therapeutics, a privately held biopharmaceutical company, announced a global collaboration to develop encapsulated cell therapies for potentially treating Type 1 diabetes. The deal is worth up to $473 million. Sigilon is focused on discovering and developing “living therapeutics” using its Afibromer technology product platform.
- Source: Sigilon Therapeutics
- 504
- April 10, 2018
diabetes Market Views
Boehringer Ingelheim and OSE Immunotherapeutics Ink $1.4B Deal

Boehringer Ingelheim, headquartered in Ingelheim, Germany, and OSE Immunotherapeutics, based in Nantes, Frances, signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.
- Source: Pharmalive
- 449
- April 10, 2018
Market Views myeloid cancers OSE-172

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.